Aim: To demonstrate the clinical value of epithelial membrane protein 3 (EMP3) with bioinformatic analysis and clinical data, and then to establish a practical nomogram predictive model with bicenter validation.
Methods: The data from CGGA and TCGA database were used to analyze the expression of EMP3 and its correlation with clinical prognosis. Then, we analyzed EMP3 expression in samples from 179 glioma patients from 2013 to 2017. Univariate and multivariate cox regression were used to predict the prognosis with multiple factors. Finally, a nomogram to predict poor outcomes was formulated. The accuracy and discrimination of nomograms were determined with ROC curve and calibration curve in training and validation cohorts.
Results: EMP3 was significantly higher in higher-grade glioma and predicted poor prognosis. In multivariate analysis, high expression of EMP3 (HR = 2.842, 95% CI 1.984-4.071), WHO grade (HR = 1.991, 95% CI 1.235-3.212), and IDH1 mutant (HR = 0.503, 95% CI 0.344-0.737) were included. The nomogram was constructed based on the above features, which represented great predictive value in clinical outcomes.
Conclusion: This study demonstrated EMP3 as a novel predictor for clinical progression and clinical outcomes in glioma. Moreover, the nomogram with EMP3 expression represented a practical approach to provide individualized risk assessment for glioma patients.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC8446216 | PMC |
| http://dx.doi.org/10.1111/cns.13701 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Potential of epithelial membrane protein 3 as a novel therapeutic target for human breast cancer.
Oncol Rep
January 2025
Department of Food Safety Hygiene and Risk Management, College of Medicine, National Cheng Kung University, Tainan 701401, Taiwan, R.O.C.
Article Synopsis
- Amplification of the HER2 receptor and overexpression of estrogen and progesterone receptors are crucial for planning breast cancer treatments, but resistance to drugs is common, highlighting the need for new advances.
- This study is the first to reveal that EMP3, a membrane protein, interacts with HER2 in breast cancer, promoting cell growth, invasion, and migration while increasing estrogen and progesterone receptor levels.
- Knocking down EMP3 reduced breast cancer cell growth and increased sensitivity to the drug trastuzumab, suggesting that targeting EMP3 could be a promising new treatment strategy for patients, especially in those with co-expression of EMP3 and HER2.
Introduction: Limited success to date in development of drugs that target hallmark Alzheimer disease (AD) proteins as a means to slow AD-related cognitive decline has sparked interest in approaches focused on cognitive resilience. We sought to identify transcriptome signatures among brain donors with neuropathologically confirmed AD that distinguish those with cognitive impairment from those that were cognitively intact.
Methods: We compared gene expression patterns in brain tissue from donors in four cohorts who were cognitively and pathologically normal (controls), met clinical and pathological criteria for AD (SymAD), or were cognitively normal prior to death despite pathological evidence of AD (cognitively resilient or AsymAD).
Protein level of epithelial membrane protein (EMP) 1, EMP 2, and EMP 3 in carcinoma of unknown primary.
Neoplasma
October 2024
Department of Pathology, Yonsei University College of Medicine, Seoul, South Korea.
Carcinoma of unknown primary (CUP) is defined as a metastatic carcinoma whose primary site cannot be determined, and the absence of a known primary tumor in CUP poses a significant challenge in treatment planning. The purpose of this study was to investigate the protein level of epithelial membrane proteins (EMP) 1, EMP 2, and EMP 3 in CUP and explore their clinical implications. Tissue microarrays were constructed using samples from 72 CUP cases.
View Article and Find Full Text PDFIdentifying a CD8T cell signature in the tumor microenvironment to forecast gastric cancer outcomes from sequencing data.
J Gastrointest Oncol
October 2024
Department of Breast and Thyroid Surgery, Cancer Hospital Affiliated to Xinjiang Medical University, Xinjiang Medical University, Urumqi, China.
Background: The tumor microenvironment (TME) could be critical in carcinogenesis, immune evasion, and treatment response. TME-related genes are limited in their ability to predict gastric cancer (GC) outcomes. We utilized data from The Cancer Genome Atlas (TCGA) to investigate the functional roles of TME-related genes in GC.
View Article and Find Full Text PDFMeasuring attitudes towards ethnic minority patients: the revalidated REMP-3 instrument for graduate healthcare practitioners.
Int J Equity Health
November 2024
Faculty of Medicine and Health Sciences, Department of Public Health and Primary Care, Research Group Equity in Health Care, Quality & Safety Ghent, Ghent University, University Hospital, Campus entrance 42, C. Heymanslaan 10, Ghent, 9000, Belgium.
Objective: Measuring intercultural attitudes can aid in understanding and addressing persistent inequities in healthcare. Instead of creating new instruments, several sources call for a more rigorous revalidation of existing instruments towards a more broad population. As an example of such an existing instrument, the EMP-3 (Ethnic Minority Patients) focuses on the attitudes of physicians towards ethnic minority patients.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!